Etoposide versus methotrexate in small cell bronchial carcinoma. A randomized study of two types of four-drug chemotherapy regimens.
Seventy-nine patients with small bronchial carcinoma randomly received cyclophosphamide, doxorubicin, vincristine, and methotrexate, alternating after four cycles with cyclophosphamide, lomustine, vincristine and methotrexate or the same with replacement of methotrexate by etoposide in lomustine cycles. Patients with limited disease received radiotherapy with 40 Gy. In 34 patients with extensive disease the total response in the groups with and without etoposide was 89% and 69% and the median survival 10.9 and 8.2 months respectively. In 45 patients with limited disease, the complete remission rates in the groups with and without etoposide were 57% and 67%, partial remission rates 38% and 25%, and the median survival times 12.3 and 17.8 months respectively. The disease-free survival exceeding 5 years in the respective groups was 4.2% and 14.3%. A slightly better response in extensive disease and a tendency to better long-term survival in limited disease was noted but the price was increased toxicity in the latter group.